Oligonucleotide Synthesis Market Overview
Oligonucleotide synthesis is the chemical process of creating short nucleotide sequences, known as oligonucleotides, for molecular biology, biotechnology, and therapeutic applications. These synthetic DNA or RNA strands are used in genetic analysis, diagnostics, and therapeutics. Advancements in this technology have led to personalized medicine, RNA-based vaccines, and targeted therapies for genetic diseases. The market for synthetic oligonucleotides continues to expand due to innovations in genomics, biopharmaceuticals, and diagnostics.
Key Takeaways
- The growing adoption of oligonucleotide-based therapeutics and precision medicine is emerging as a key industry trend, with pharmaceutical and biotechnology companies expanding investments in advanced DNA and RNA synthesis technologies to support next-generation drug development and personalized healthcare.
- North America maintains a leading position in the global oligonucleotide synthesis market, driven by its strong biopharmaceutical ecosystem, significant research and development investments, well-established contract manufacturing capabilities, and the increasing number of clinical programs focused on nucleic acid therapeutics.
- Asia-Pacific is projected to witness the fastest growth during the forecast period, supported by expanding biotechnology infrastructure, rising government funding for genomic research, increasing pharmaceutical manufacturing activities, and growing demand for cost-effective oligonucleotide production services.
- The rapid advancement of RNA-based therapeutics, antisense oligonucleotides, siRNA, mRNA technologies, and gene-editing platforms is accelerating the demand for high-purity oligonucleotide synthesis solutions across research, clinical, and commercial applications.
- Increasing utilization of synthetic oligonucleotides in molecular diagnostics, PCR, next-generation sequencing (NGS), biomarker discovery, and companion diagnostics is strengthening market growth as precision diagnostics become an essential component of modern healthcare.
- Industry participants are increasingly prioritizing investments in automated synthesis platforms, scalable GMP manufacturing, advanced purification technologies, and quality assurance capabilities to address the growing commercial demand for therapeutic-grade oligonucleotides.
- Expanding collaborations between pharmaceutical companies, biotechnology firms, academic research institutions, and contract development and manufacturing organizations (CDMOs) are creating significant opportunities to accelerate innovation, improve manufacturing scalability, and support the commercialization of oligonucleotide-based therapeutics worldwide.
Oligonucleotide Synthesis Market Scope
| Metrics | Details |
| CAGR | 9.0% |
| Market Size Available for Years | 2023-2033 |
| Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product Type, Application, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report – Request for Sample
Oligonucleotide Synthesis Market Dynamics: Drivers & Restraints
Increased investment in pharmaceutical and biotechnology companies
The oligonucleotide synthesis market is boosted by substantial investment from government funds and research, promoting innovation and therapeutic exploration. However, challenges like cost erosion and lack of standardized guidelines pose potential hindrances. Therefore, stakeholders must navigate these market dynamics to fully capitalize on the market's growth potential in the near future.
For instance, in June 2024, GSK plc announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million). Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.
Erosion of costs
The oligonucleotide synthesis market faces challenges due to cost erosion, uncertainty in therapeutic oligo guidelines, and a lack of unified guidelines. These factors could impact profit margins and market sustainability, hindering the seamless progression of oligonucleotide synthesis technologies. It is crucial for industry stakeholders to effectively address these challenges for sustained growth in molecular diagnostics and clinical applications.
Oligonucleotide Synthesis Market Segmentation Analysis
The global oligonucleotide synthesis market is segmented based on product type, application, end-user, and region.
The reagents from the product type segment accounted for approximately 41.3% of the oligonucleotide synthesis market share
The reagents from the product type segment accounted for approximately 41.3%. The global oligonucleotide synthesis market relies heavily on reagents, including phosphoramidites, solvents, catalysts, and capping agents, which control the efficiency, accuracy, and yield of the synthesis process. High-quality reagents ensure the fidelity of oligonucleotide chains and minimize errors. The market for synthesis reagents has expanded significantly due to the growing demand for precise and reliable oligonucleotides in gene editing, diagnostics, and therapeutics. The success of oligonucleotide-based research and the development of novel therapeutics are directly linked to reagent quality advancements.
For instance, in September 2024, Emp Biotech partnered with Atom Scientific to distribute its high-quality oligonucleotide synthesis reagents in the UK and Ireland, marking an exclusive distribution partnership for the company's oligonucleotide synthesis products.
Oligonucleotide Synthesis Market Regional Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market.
For instance, in May 2024, Codexis, Inc. a leading enzyme engineering company, announced it successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Codexis has achieved the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety, providing a significant proof of process for alternative manufacturing methods in the RNAi therapeutics industry.
Moreover, the American Cancer Society predicts that in the year 2024, there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. As the demand for new and improved cancer treatments increases, the requirement for synthetic oligonucleotides is growing. The synthetic oligonucleotides are used in a variety of research and diagnostic applications.
Oligonucleotide Synthesis Market Competitive Landscape
The major global players in the market include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (a Maravai LifeSciences company), Merck KGaA (Sigma-Aldrich), ATDBio Ltd among others.
Key Developments of the Oligonucleotide Synthesis Market
January 2026: Codexis signed an evaluation agreement with Axolabs (LGC Group) to assess its ECO Synthesis® Manufacturing Platform for enzymatic RNA oligonucleotide production. The collaboration aims to advance next-generation oligonucleotide therapeutics manufacturing through scalable enzymatic synthesis, delivering higher yields, lower waste generation, and improved manufacturing efficiency for RNA-based medicines.
- November 2025: BioSpring and metabion announced a strategic collaboration to accelerate therapeutic oligonucleotide development from early discovery through commercial manufacturing. The partnership combines metabion's high-throughput oligonucleotide synthesis capabilities with BioSpring's GMP manufacturing and analytical expertise to reduce development timelines and support global oligonucleotide drug innovation.
- October 2025: BioSpring entered a strategic licensing partnership with Luxna Biotech to manufacture therapeutic oligonucleotides incorporating Luxna's proprietary XNA amidite technologies (AmNA™, scpBNA™, and 5′-CP™). The collaboration expands access to next-generation XNA chemistries that enhance oligonucleotide binding affinity, stability, and safety, supporting the development of advanced antisense and RNA therapeutics.
Why Purchase the Report?
- To visualize the global oligonucleotide synthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the oligonucleotide synthesis market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global oligonucleotide synthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
